145 related articles for article (PubMed ID: 31812284)
1. [Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions].
Penel N; Ryckewaert T; Orbach D
Bull Cancer; 2020 Mar; 107(3):375-380. PubMed ID: 31812284
[TBL] [Abstract][Full Text] [Related]
2. Desmoid Fibromatosis: Management in an Era of Increasing Options.
Ratan R; Roland CL; Bishop AJ
Curr Oncol Rep; 2021 Mar; 23(4):41. PubMed ID: 33719012
[TBL] [Abstract][Full Text] [Related]
3. Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management.
Penel N; Ryckewaert T; Le Deley MC
Am J Clin Oncol; 2019 Dec; 42(12):958. PubMed ID: 31764064
[No Abstract] [Full Text] [Related]
4. Desmoid tumors: who, when and how to treat?
Mikhael R; Smith M; Tzanis D; Watson S; Miah AB; Bonvalot S
Curr Opin Oncol; 2022 Jul; 34(4):335-341. PubMed ID: 35837705
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of low-dose chemotherapy with methotrexate and vinblastine for patients with extra-abdominal desmoid-type fibromatosis: a systematic review.
Shimizu K; Hamada S; Sakai T; Koike H; Yoshida M; Nishida Y
Jpn J Clin Oncol; 2020 Apr; 50(4):419-424. PubMed ID: 31845730
[TBL] [Abstract][Full Text] [Related]
6. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract][Full Text] [Related]
7. Desmoid tumours stalled by sorafenib.
Wrighton KH
Nat Rev Clin Oncol; 2019 Apr; 16(4):209. PubMed ID: 30664677
[No Abstract] [Full Text] [Related]
8. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Orbital Desmoid-type Fibromatosis With Sorafenib.
Downie EM; Amend CE; Miranda A; Burkat CN
Ophthalmic Plast Reconstr Surg; 2022 Sep-Oct 01; 38(5):e144-e147. PubMed ID: 35470290
[TBL] [Abstract][Full Text] [Related]
10. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Physician's Systemic Treatment Preferences for Patients with Advanced Desmoid-Type Fibromatosis: Experience-Based Medicine in the Absence of High-Level Evidence.
Schöffski P; Requilé A; van Cann T
Oncol Res Treat; 2018; 41(4):214-219. PubMed ID: 29562221
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with methotrexate and vinblastine for surgically unresectable, aggressive fibromatosis.
Park KH; Choi YJ; Kim KW; Ro KH; Kang CH; Song SH; Park JH
Jpn J Clin Oncol; 2016 Sep; 46(9):845-9. PubMed ID: 27365524
[TBL] [Abstract][Full Text] [Related]
13. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.
Sparber-Sauer M; Orbach D; Navid F; Hettmer S; Skapek S; Corradini N; Casanova M; Weiss A; Schwab M; Ferrari A
Br J Cancer; 2021 May; 124(10):1637-1646. PubMed ID: 33723397
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.
Robles J; Keskinyan VS; Thompson M; Davis JT; Mater DV
Pediatr Hematol Oncol; 2020 Aug; 37(5):445-449. PubMed ID: 32129687
[No Abstract] [Full Text] [Related]
15. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
16. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma.
Iacovelli R; Verzoni E; Grassi P; Farcomeni A; de Braud F; Procopio G
Tumori; 2014; 100(6):e282-5. PubMed ID: 25688511
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib, a promising option for the treatment of aggressive fibromatosis.
Szucs Z; Messiou C; Wong HH; Hatcher H; Miah A; Zaidi S; van der Graaf WT; Judson I; Jones RL; Benson C
Anticancer Drugs; 2017 Apr; 28(4):421-426. PubMed ID: 28099210
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review.
Tsukamoto S; Takahama T; Mavrogenis AF; Tanaka Y; Tanaka Y; Errani C
Musculoskelet Surg; 2023 Mar; 107(1):7-18. PubMed ID: 35150408
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
Sonpavde G; Je Y; Schutz F; Galsky MD; Paluri R; Rosenberg JE; Bellmunt J; Choueiri TK
Crit Rev Oncol Hematol; 2013 Jul; 87(1):80-9. PubMed ID: 23317774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
